This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Segura, J. Articles by Ruilope, L. M. Search for Related Content PubMed PubMed Citation Articles by Segura, J. Articles by Ruilope, L. M. Pubmed/NCBI databases Medline Plus Health Information High Blood Pressure Related Collections Secondary prevention Clinical Studies Other Treatment

(Hypertension. 2001;38:645.)
© 2001 American Heart Association, Inc.

Renal Factors

ACE Inhibitors and Appearance of Renal Events in Hypertensive Nephrosclerosis

Julián Segura; Carlos Campo; José L. Rodicio; Luis M. Ruilope

Unidad de Hipertensión, Hospital 12 de Octubre, Madrid, Spain.

Correspondence to Dr Julián Segura, Unidad de Hipertensión Arterial, Hospital 12 de Octubre, Madrid 28041, Spain. E-mail jsegurad{at}senefro.org

Abstract

Abstract—— Nephrosclerosis constitutes a major cause of end-stage renal disease. Independently of blood pressure control, ACE inhibitors (ACEIs) are considered to be more nephroprotective than other antihypertensive agents. We have reviewed the long-term evolution of renal function in our series of essential hypertensive patients diagnosed as having nephrosclerosis when first seen in our unit. The analysis was performed depending on whether or not their antihypertensive therapy contained an ACEI alone or in combination for the whole follow-up. The end point was defined as the confirmation of a 50% reduction in creatinine clearance or entry in a dialysis program. A historical cohort of 295 patients was included in the analysis. Mean follow-up was 7.4±3.9 years. Diabetes prevalence was higher in ACEI-treated patients (25.7% versus 7.1%, P=0.000), but the diagnosis of diabetic nephropathy could not be confirmed on clinical grounds, including renal biopsy. Twenty-three out of 183 (12.6%) patients in the ACEI group and 23 out of 112 (20.5%) patients in the non-ACEI group experienced a renal event (P=0.0104 by log rank test). Similar results were observed when only nondiabetic patients were considered for the analysis. Cox regression analysis showed that baseline serum creatinine, absence of ACEI administration, mean proteinuria during follow-up, and age were independent predictors for the development of a renal event. In hypertensive nephrosclerosis, therapy containing an ACEI alone or in combination significantly reduces the incidence of renal events. This effect is independent of blood pressure control.

Key Words: hypertension, arterial • nephrosclerosis • renal insufficiency • renin-angiotensin system • angiotensin-converting enzyme inhibitors • antihypertensive therapy

This article has been cited by other articles:

				L. M. Ruilope and J. Segura Blood pressure lowering or selection of antihypertensive agent: which is more important? Nephrol. Dial. Transplant., April 1, 2006; 21(4): 843 - 845. [Full Text] [PDF]

				J. A Garcia-Donaire and L. M Ruilope Spotlight on Renin: Cardiovascular outcomes in chronic kidney disease and suppression of the renin-angiotensin system Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1): 56 - 58. [PDF]

				J. Segura, J. A. Garcia-Donaire, and L. M. Ruilope Calcium Channel Blockers and Renal Protection: Insights from the Latest Clinical Trials J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S64 - S66. [Abstract] [Full Text] [PDF]

				L. M. Ruilope The Kidney as a Sensor of Cardiovascular Risk in Essential Hypertension J. Am. Soc. Nephrol., November 1, 2002; 13(90003): S165 - 168. [Abstract] [Full Text]

				L. M. Ruilope, D. J. van Veldhuisen, E. Ritz, and T. F. Luscher Renal function: the Cinderella of cardiovascular risk profile J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1782 - 1787. [Abstract] [Full Text] [PDF]